GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stryker Corp (NYSE:SYK) » Definitions » Cash Flow from Financing

Stryker (Stryker) Cash Flow from Financing : $-1,594 Mil (TTM As of Dec. 2023)


View and export this data going back to 1988. Start your Free Trial

What is Stryker Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Stryker paid $0 Mil more to buy back shares than it received from issuing new shares. It received $35 Mil from issuing more debt. It paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent $285 Mil paying cash dividends to shareholders. It spent $36 Mil on other financial activities. In all, Stryker spent $286 Mil on financial activities for the three months ended in Dec. 2023.


Stryker Cash Flow from Financing Historical Data

The historical data trend for Stryker's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stryker Cash Flow from Financing Chart

Stryker Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 -11.00 -2,365.00 -749.00 -1,594.00

Stryker Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -446.00 -481.00 -405.00 -422.00 -286.00

Stryker Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Stryker's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Stryker's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,594 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stryker  (NYSE:SYK) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Stryker's issuance of stock for the three months ended in Dec. 2023 was $0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Stryker's repurchase of stock for the three months ended in Dec. 2023 was $0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Stryker's net issuance of debt for the three months ended in Dec. 2023 was $35 Mil. Stryker received $35 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Stryker's net issuance of preferred for the three months ended in Dec. 2023 was $0 Mil. Stryker paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Stryker's cash flow for dividends for the three months ended in Dec. 2023 was $-285 Mil. Stryker spent $285 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Stryker's other financing for the three months ended in Dec. 2023 was $-36 Mil. Stryker spent $36 Mil on other financial activities.


Stryker Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Stryker's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Stryker (Stryker) Business Description

Address
2825 Airview Boulevard, Kalamazoo, MI, USA, 49002
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.
Executives
Srikant Datar director ICF INTERNATIONAL, INC., 9300 LEE HIGHWAY, FAIRFAX VA 22031
Berry William E Jr officer: Vice President, Controller 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Kevin Lobo officer: Group Pres., Neurotech & Spine STRYKER, 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Viju Menon officer: Group President 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Allan C. Golston director 2825 AIRVIEW BLVD., KALAMAZOO MI 49002
Ronda E Stryker director 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Robert S Fletcher officer: VP, Chief Legal Officer 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
James Andrew Pierce officer: Group President 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Glenn S Boehnlein officer: Vice President, CFO 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
M Kathryn Fink officer: VP, Global Human Resources 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Spencer S Stiles officer: Group President 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Giovanni Caforio director BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Timothy J Scannell officer: Group President 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Roch Doliveux director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Katherine Ann Owen officer: VP 2825 AIRVIEW BLVD., KALAMAZOO MI 49002

Stryker (Stryker) Headlines

From GuruFocus

Q4 2021 Stryker Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Stryker Corp To Host Investor Day Transcript

By GuruFocus Research 01-23-2024

Q4 2020 Stryker Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2023 Stryker Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2022 Stryker Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2020 Stryker Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024